R&D channel feed

Fate's close­ly watched stem cell-de­rived NK pro­gram rais­es red flag over dura­bil­i­ty of re­sponse

4 years ago
Cell/Gene Tx

Covid-19 man­u­fac­tur­ing roundup: Sene­gal looks to get in the man­u­fac­tur­ing mix; As­pen vac­cine ex­ports part of tem­po­rary deal

4 years ago
Manufacturing

As Cu­ria ex­pands, it will add API site in up­state New York; In bat­tle against food al­ler­gies, Al­ladapt to build site to prep for PhI­II tri­als

4 years ago
Manufacturing

Mov­ing be­yond just sol­id dose, Re­cro Phar­ma is head­ed to San Diego with ac­qui­si­tion

4 years ago

J&J hunts for a Ry­bre­vant la­bel add just months af­ter rare lung can­cer ap­proval

4 years ago

UK's cost-ef­fec­tive­ness gate­keep­er wants to pro­vide faster ac­cess to more new drugs

4 years ago
Pharma

Next-gen pso­ri­a­sis drug ri­val­ry be­tween Bris­tol My­ers and Nim­bus spills in­to a le­gal bat­tle

4 years ago
Pharma

Sev­er­al months af­ter re­brand­ing, an old Mar­tin Shkre­li com­pa­ny touts promis­ing piv­otal da­ta in a rare kid­ney dis­or­der

4 years ago

As Biden sig­nals in­ter­est in link­ing drug prices with R&D costs, new study finds costs per NME are in­creas­ing

4 years ago

Boehringer In­gel­heim scraps $600M+ lung can­cer pro­gram with Cure­Vac, as the biotech preps its sec­ond Covid-19 shot

4 years ago
Deals

Eli Lil­ly un­veils piv­otal da­ta from the star of its Der­mi­ra buy­out. But can it ri­val Dupix­ent in atopic der­mati­tis?

4 years ago

Covid-19 roundup: Tiny sam­ple size leads FDA to turn down Rigel's EUA; Seat­tle biotech to co-de­vel­op mR­NA vac­cine in South Ko­rea

4 years ago
Coronavirus

As US re­view of Eli Lil­ly-part­nered PD-1 gets un­der­way, In­novent touts an­oth­er front­line win in Chi­na

4 years ago
China

Mer­ck takes home an FDA win for a Roger Perl­mut­ter fa­vorite, po­ten­tial­ly crack­ing open big mar­ket

4 years ago
FDA+

Ipsen with­draws NDA for rare bone dis­ease treat­ment less than 3 months af­ter win­ning pri­or­i­ty re­view

4 years ago
FDA+

Mer­ck nabs ap­proval for Keytru­da com­bo in kid­ney can­cer af­ter prov­ing it can ex­tend sur­vival

4 years ago
FDA+

Heat Bi­o­log­ics goes back to San An­to­nio to build a re­search and man­u­fac­tur­ing fa­cil­i­ty

4 years ago
Manufacturing

Aim­ing to brush last year's flop aside, Ful­crum sees shares sky­rock­et on ear­ly look at sick­le cell pro­gram

4 years ago

Pri­or­i­ty re­view vouch­er up­dates: Who's won PRVs, who's bought them, and how much they're sell­ing for

4 years ago
FDA+

Blue­bird forced to halt tri­als af­ter a can­cer-like case, pulls gene ther­a­pies from Eu­rope fol­low­ing pric­ing back­lash — shares slammed

4 years ago
Cell/Gene Tx
FDA+

Let­ter from FDA out­lin­ing de­fi­cien­cies for lead drug caus­es Ax­some stock to crater. Is a CRL on the way?

4 years ago
Pharma
FDA+

On a quest to treat new­ly di­ag­nosed lym­phoma pa­tients, Roche teas­es pos­i­tive piv­otal da­ta

4 years ago

As­traZeneca and Dai­ichi Sankyo con­tin­ue to flesh out En­her­tu plans, claim­ing win in ear­li­er breast can­cer line

4 years ago

Dicer­na's RNAi drug shows 'in­con­sis­ten­t' re­sults in rare kid­ney dis­ease, tank­ing shares de­spite tri­al win

4 years ago
First page Previous page 161162163164165166167 Next page Last page
A service from the Financial Times